Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.
1. A method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside comprising contacting the cell with a composition comprising (i) at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons, and (ii) at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside, in an amount and concentration effective to enhance uptake of the anti-cancer agent by the cell, wherein the antibody causes permeability defects within the cell membrane and wherein said multimeric antibody recognizing the OAcGD2 ganglioside comprises a) a light chain variable region (VL) polypeptide having the amino acid sequence SEQ ID NO: 1 and b) a heavy chain variable region (VH) having the amino acid sequence SEQ ID NO: 2.
2. The method of claim 1 , wherein the cell expressing the OAcGD2 ganglioside is a cancer cell.
3. The method of claim 1 , wherein said method is for further treating cancer expressing the OAcGD2 ganglioside in a patient, comprising administering to a patient in need thereof an effective amount of the composition.
4. A method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside comprising contacting the cell with a composition comprising (i) at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons, and (ii) at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside in an amount and concentration effective to enhance uptake of the anti-cancer agent by the cell, wherein the antibody causes permeability defects within the cell membrane and wherein the at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside comprises:
the light chain variable region (VL) polypeptide having the amino acid sequence selected in the group comprising or consisting of SEQ ID NO: 39 and SEQ ID NO: 40; and
the heavy chain variable region (VH) having the amino acid sequence selected in the group comprising or consisting of SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50 and SEQ ID NO: 51.
5. The method of claim 1 , wherein the multimeric fragment of the antibody recognizing the OAcGD2 ganglioside is in the form of single chain fragments of heavy and light chain variable regions (scFv).
6. The method of claim 1 , wherein the multimeric fragment of the antibody recognizing the OAcGD2 ganglioside is a single-chain part of a chimeric antigen receptor (CAR).
7. A method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside comprising contacting the cell with a composition comprising (i) at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons, and (ii) at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside in an amount and concentration effective to enhance uptake of the anti-cancer agent by the cell, wherein the antibody causes permeability defects within the cell membrane and wherein the at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside comprises:
the light chain variable region (VL) polypeptide having the amino acid sequence selected in the group comprising or consisting of SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO:39 and SEQ ID NO: 40, and
the heavy chain variable region (VH) having the amino acid sequence selected in the group comprising or consisting of SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO: 47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50 and SEQ ID NO: 51.
8. A method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside comprising contacting the cell with a composition comprising (i) at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons, and (ii) at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside in an amount and concentration effective to enhance uptake of the anti-cancer agent by the cell, wherein the antibody causes permeability defects within the cell membrane and wherein the at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside comprises:
a) a light chain variable region (VL) polypeptide having the amino acid sequence SEQ ID NO: 14; and
b) a heavy chain variable region (VH) having the amino acid sequence SEQ ID NO: 15.
9. The method of claim 1 , wherein the at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside comprises:
a) a heavy chain comprising three heavy chain complementary regions (CDRs) having the amino acid sequences SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18, and a heavy chain framework sequence from an immunoglobulin heavy chain, and
b) a light chain comprising three light chain complementary regions (CDRs) having the amino acid sequences SEQ ID NO:19, SEQ ID NO:20 and SEQ ID NO:21, and a light chain framework sequence from an immunoglobulin light chain.
10. The method of claim 1 , wherein said at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside is an immunoconjugate.
11. The method of claim 1 , wherein the at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons is selected from the group comprising or consisting of anti-cancer agents such as alkylating agents, anti-metabolites, anti-tumor antibodies, anti-tumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, tyrosine kinase inhibitors, corticosteroids, hormones or hormone-like drugs, cytokines, nucleoside analogs, nucleic acids, such double-stranded synthetic short RNA molecules (miRNAs) or synthetic DNA/RNA-like oligonucleotides (ASOs).
12. The method of claim 1 , wherein the at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons is unable to cross the cell membrane of cancer cells by itself.
13. The method of claim 3 , wherein the cancer expressing the OAcGD2 ganglioside is selected from the group comprising or consisting of neuroblastoma, glioma, retinoblastoma, Ewing's family of tumors, sarcoma small cell lung cancer, breast cancer, melanoma, metastatic renal carcinoma, head and neck cancer and hematological cancers.
14. The method of claim 13 , wherein the at least one anti-cancer agent is selected from the group comprising or consisting of cyclophosphamide, doxorubicin, topotecan, irinotecan, temozolomide (TMZ), retinoic acid (RA), 5-Fluorouracil (5-FU), fludarabine, carboplatin and cisplatin.
15. The method of claim 3 , wherein the at least one anti-cancer agent is temozolomide, topotecan, irinotecan, fludarabine, cyclophosphamide or a mixture thereof and the cancer expressing the OAcGD2 ganglioside is neuroblastoma.
16. The method of claim 3 , wherein said method is for further increasing the efficacy of a cancer expressing the OAcGD2 ganglioside treatment comprising an anti-cancer agent, wherein the at least one anti-cancer agent has a molecular mass ranging from 100 Daltons to 200,000 Daltons.
17. The method of claim 3 , wherein said method is for further increasing sensitivity to an anti-cancer agent in a patient suffering from a cancer expressing the OAcGD2 ganglioside, wherein the at least one anti-cancer agent has a molecular mass ranging from 100 Daltons to 200,000 Daltons.
18. A method of delaying development of cancer resistant to an anti-cancer agent in a patient suffering from a cancer expressing the OAcGD2 ganglioside, comprising administering to a patient in need thereof an effective amount of a composition comprising: (i) at least one anti-cancer agent having a molecular mass ranging from 100 Daltons to 200,000 Daltons, (ii) at least one multimeric antibody or multimeric fragment thereof recognizing the OAcGD2 ganglioside, wherein the multimeric antibody recognizing the OAcGD2 ganglioside comprises a) a light chain variable region (VL) polypeptide having the amino acid sequence SEQ ID NO: 1 and b) a heavy chain variable region (VH) having the amino acid sequence SEQ ID NO: 2.